Scarica l'app Stockscreener
37.93
3.93%
-1.55
Dopo l'orario di chiusura:
37.93
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$39.48
Aprire:
$38.9
Volume 24 ore:
1.88M
Relative Volume:
1.00
Capitalizzazione di mercato:
$4.55B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-7.211
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
-4.72%
1M Prestazione:
-16.51%
6M Prestazione:
-29.51%
1 anno Prestazione:
-43.85%
Intervallo 1D:
$37.45
$39.28
Intervallo di 1 settimana:
$37.45
$40.22
Portata 52W:
$32.74
$68.76
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
37.93 | 4.55B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach - Benzinga
Bristol Myers' Camzyos Update Boosts Prospects for Cytokinetics (CYTK) | BMY Stock News - GuruFocus
Stifel maintains Cytokinetics stock buy rating, $87 target By Investing.com - Investing.com India
US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble - insights.citeline.com
Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now? - Yahoo
10 Best High Short Interest Stocks to Buy Now - Insider Monkey
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics Strategic Talent Push: 13 New Hires Receive Major Equity Package Worth $3.9M - Stock Titan
Cytokinetics director John Henderson sells $123,325 in stock By Investing.com - Investing.com South Africa
Cytokinetics director John Henderson sells $123,325 in stock - Investing.com Australia
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It - MSN
Cytokinetics (CYTK) Gains Favor as Key Trial by Bristol-Myers Fa - GuruFocus
Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten - insights.citeline.com
JMP maintains $78 target on Cytokinetics stock after trial update By Investing.com - Investing.com Canada
Cytokinetics falls after rival Bristol Myers' heart drug fails trial - TradingView
BofA Adjusts Price Target for Cytokinetics (CYTK) Amid Competiti - GuruFocus
Bristol Myers stumbles in bid to widen heart drug’s use - Yahoo Finance
Citi Analysts Include Cytokinetics (CYTK) in 2025 North America Focus List | CYTK Stock News - GuruFocus
Cytokinetics, IncorporatedCommon Stock (NQ: CYTK - FinancialContent
Cytokinetics CEO Robert Blum sells $183,850 in stock By Investing.com - Investing.com South Africa
Cytokinetics CEO Robert Blum sells $183,850 in stock - Investing.com Australia
Cytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapy - MSN
JMP reiterates Cytokinetics stock with $78 target on HCM trial optimism - Investing.com Canada
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - GlobeNewswire
Exclusive: Cardiometabolic biotech gets $57.5M Series B, with help from Cytokinetics - Endpoints News
Optimistic Buy Rating on Cytokinetics Driven by Promising Aficamten Trial Outcomes - TipRanks
Cytokinetics stock plunges to 52-week low of $33.67 By Investing.com - Investing.com Canada
Cytokinetics’ CK-4021586 improves cardiac function in HFpEF - BioWorld MedTech
Cytokinetics (NASDAQ:CYTK) Given "Buy" Rating at HC Wainwright - MarketBeat
Cytokinetics EVP sells $72,360 in stock By Investing.com - Investing.com South Africa
Cytokinetics EVP sells $72,360 in stock - Investing.com Australia
Cytokinetics' SWOT analysis: aficamten potential drives stock outlook - Investing.com
Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health By Investing.com - Investing.com Canada
Cytokinetics CCO Andrew Callos sells $103k in stock By Investing.com - Investing.com India
Cytokinetics CCO Andrew Callos sells $103k in stock - Investing.com
Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health - Investing.com
Cytokinetics director Robert Harrington sells shares worth $17,743 By Investing.com - Investing.com South Africa
Cytokinetics director Robert Harrington sells shares worth $17,743 - Investing.com Australia
H.C. Wainwright maintains $120 target on Cytokinetics stock By Investing.com - Investing.com Canada
Cytokinetics stock holds $78 target from JMP amid trial results By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains overweight on Cytokinetics stock By Investing.com - Investing.com Canada
Cytokinetics stock holds $78 target from JMP amid trial results - Investing.com
CYTK Gains as EWTX Data and Fundraising Impact Stock Movement - GuruFocus
Why These Two Biotech Stocks Just Diverged - Investor's Business Daily
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - Investopedia
Raymond James maintains Cytokinetics stock with $81 target By Investing.com - Investing.com UK
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
Cytokinetics stock rises on Edgewise data for lead drug (EWTX) - Seeking Alpha
Cytokinetics CEO compensation jumps 64%, thanks in large part to stock awardsSan Francisco Business Times - The Business Journals
Cytokinetics CEO Makes Major Stock Move! - TipRanks
Former Gilead legal star departs Cytokinetics as crucial FDA ruling approachesSan Francisco Business Times - The Business Journals
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):